Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics BRCA Test to be Reimbursed in Japan

NEW YORK – Myriad Genetics' BRACAnalysis Diagnostic System will be reimbursed in Japan as a test to identify whether individuals with hereditary breast and ovarian cancer syndrome have BRCA1/2 mutations.

Japan's Ministry of Health, Labor and Welfare (MHLW) granted regulatory approval for the diagnostic in November of last year for this indication. In February 2019, the MHLW approved the test as a companion diagnostic for the PARP inhibitor olaparib (AstraZeneca's Lynparza) in ovarian cancer, and in March 2018, it approved it as a companion diagnostic for the same drug in metastatic inoperable or recurrent breast cancer. 

The most recent reimbursement decision means the test will be covered when physicians order it for patients who meet the following criteria from the Japanese Organization of Hereditary Breast and Ovarian Cancer: their family members have BRCA1/2 mutations; they have certain personal or family history of breast cancer, ovarian cancer, or male breast cancer; or somatic testing reveals they may have  BRCA1/2 mutation and they are eligible for a PARP inhibitor.

Myriad estimates there are more than 25,000 people who meet this testing criteria in Japan, where it has partnered with SRL, a subsidiary of Miraca Group, to commercialize BRACAnalysis.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.